Study of Antithymocyte Globulin for Treatment of New-onset T1DM (START)

Antithymocyte globulin (e.g., Thymoglobulin) is an antibody preparation that is commonly used to treat and prevent organ transplant rejection. The START trial aims to determine whether antithymocyte globulin (ATG) treatment can halt the progression of newly diagnosed type 1 diabetes when given within 12 weeks of disease diagnosis.

抗胸腺细胞球蛋白（Antithymocyte globulin，如胸腺球蛋白（Thymoglobulin））是一类临床常用的抗体制剂，可用于治疗和预防器官移植排斥反应。本START临床试验旨在明确，在新诊断1型糖尿病患者确诊后的12周内给予抗胸腺细胞球蛋白（ATG）治疗，是否能够阻断该疾病的病情进展。